We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+42.81%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$1.08B
AUM Growth
+$85.4M
Cap. Flow
-$147M
Cap. Flow %
-13.59%
Top 10 Hldgs %
60.85%
Holding
62
New
9
Increased
7
Reduced
15
Closed
21
Avg Time Held Equity + Options
3.3 quarters
Top 10 Avg Time Held Equity + Options
3.5 quarters
Top 20 Avg Time Held Equity + Options
3.5 quarters
Avg Time Held Equity only
3.5 quarters
Top 10 Avg Time Held Equity only
4 quarters
Top 20 Avg Time Held Equity only
3.7 quarters

Top Buys

Rank Stock Value
1
CRSP icon
CRISPR Therapeutics
CRSP
+$57.7M
2
XNCR icon
Xencor
XNCR
+$35.6M
3
RARE icon
Ultragenyx Pharmaceutical
RARE
+$28.4M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$24M
5
HARP
Harpoon Therapeutics, Inc. Common Stock
HARP
+$17.6M

Top Sells

Rank Stock Value
1
KYNB icon
Kyntra Bio
KYNB
+$73.6M
2
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$44.7M
3
IONS icon
Ionis Pharmaceuticals
IONS
+$39.2M
4
ASND icon
Ascendis Pharma A/S
ASND
+$27.9M
5
ASMB icon
Assembly Biosciences
ASMB
+$26.4M

Sector Composition

Rank Sector Weight
1 Healthcare 85.16%
2 Miscellaneous 14.84%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ARGX icon
1
argenx
ARGX
$51B
$103M 9.5%
825,087
– –
2018 Q4
1 quarter
KURA icon
2
Kura Oncology
KURA
$868M
$87.5M 8.07%
5,276,753
– –
2015 Q4
13 quarters
MRTX
3
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$73.3M 6.76%
1,000,000
+352,831
+55% +$24M
2018 Q4
1 quarter
CRSP icon
4
CRISPR Therapeutics
CRSP
$4.77B
$67.1M 6.18%
1,878,277
+1,669,427
+799% +$57.7M
2018 Q3
2 quarters
XNCR icon
5
Xencor
XNCR
$1.75B
$64M 5.9%
2,059,429
+1,070,411
+108% +$35.6M
2018 Q4
1 quarter
ONCE
6
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$60.2M 5.55%
529,000
-607,851
-53% -$44.7M
2018 Q3
2 quarters
IRWD icon
7
Ironwood Pharmaceuticals
IRWD
$587M
$59.5M 5.48%
5,250,219
-1,175,032
-18% -$13.1M
2015 Q4
13 quarters
KYNB icon
8
PUT
Kyntra Bio
KYNB
$23.8M
$54.4M 5.01%
+40,000
New +$54.2M
2019 Q1
0 quarters
DRNA
9
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$48.6M 4.48%
3,316,407
– –
2017 Q1
8 quarters
ASND icon
10
Ascendis Pharma A/S
ASND
$14.7B
$42.5M 3.91%
360,819
-318,927
-47% -$27.9M
2016 Q3
10 quarters
ASND icon
11
PUT
Ascendis Pharma A/S
ASND
$14.7B
$42.4M 3.91%
360,000
– –
2018 Q4
1 quarter
RARE icon
12
Ultragenyx Pharmaceutical
RARE
$1.46B
$34.5M 3.18%
+497,899
New +$28.4M
2019 Q1
0 quarters
MRTX
13
CALL
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$25.6M 2.36%
+348,900
New +$23.7M
2019 Q1
0 quarters
MYOK
14
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$24.9M 2.29%
478,574
+244,193
+104% +$11.2M
2018 Q4
1 quarter
KYNB icon
15
CALL
Kyntra Bio
KYNB
$23.8M
$24M 2.21%
17,632
-16,000
-48% -$21.7M
2017 Q4
5 quarters
ASMB icon
16
Assembly Biosciences
ASMB
$411M
$22.7M 2.09%
96,133
-104,271
-52% -$26.4M
2014 Q4
17 quarters
EIGR
17
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$22.3M 2.06%
53,188
– –
2018 Q2
3 quarters
DNTH icon
18
Dianthus Therapeutics
DNTH
$4.34B
$21M 1.94%
79,862
-6,356
-7% -$1.1M
2018 Q2
3 quarters
GOSS icon
19
Gossamer Bio
GOSS
$57.2M
$16.7M 1.54%
+9,651
New +$16.1M
2019 Q1
0 quarters
CHMA
20
DELISTED
Chiasma, Inc. Common Stock
CHMA
$15.8M 1.46%
3,043,827
+2,664,074
+702% +$11.7M
2018 Q3
2 quarters
KZR icon
21
DELISTED
Kezar Life Sciences
KZR
$15.2M 1.4%
85,647
-20,355
-19% -$4.01M
2018 Q2
3 quarters
IRWD icon
22
CALL
Ironwood Pharmaceuticals
IRWD
$587M
$14.7M 1.35%
1,295,012
-104,714
-7% -$1.17M
2017 Q3
6 quarters
HARP
23
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$12.7M 1.17%
+133,642
New +$17.6M
2019 Q1
0 quarters
RCUS icon
24
Arcus Biosciences
RCUS
$2.88B
$12.4M 1.14%
990,146
-233,349
-19% -$2.53M
2018 Q1
4 quarters
MRSN icon
25
DELISTED
Mersana Therapeutics
MRSN
$12.1M 1.12%
+92,000
New +$11.6M
2019 Q1
0 quarters
1
2 3

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q1 2019 Portfolio in Review

As of Q1 2019, EcoR1 Capital held 62 positions worth $1.08B, up 8.5% from $999M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

EcoR1 Capital withdrew a net $147M in Q1 2019, closing 21 positions and reducing 15 holdings. Its most notable exit was Ionis Pharmaceuticals, an estimated $39.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 87% a quarter earlier, followed by Miscellaneous.

Against the trend, EcoR1 Capital opened a new position in Ultragenyx Pharmaceutical worth $34.5M.

  • EcoR1 Capital's largest Q1 2019 buy was Ultragenyx Pharmaceutical: 497,899 shares worth $34.5M.
  • EcoR1 Capital added most to CRISPR Therapeutics in Q1 2019, an estimated $57.7M increase.
  • EcoR1 Capital's biggest Q1 2019 reduction was Kyntra Bio, cutting an estimated $73.6M.
  • EcoR1 Capital fully exited Ionis Pharmaceuticals in Q1 2019, selling an estimated $39.2M.
  • EcoR1 Capital's ten largest holdings make up 61% of its $1.08B portfolio in Q1 2019.
  • EcoR1 Capital opened 9 new positions and closed 21 in Q1 2019.
  • EcoR1 Capital's portfolio value rose 8.5% quarter-over-quarter to $1.08B.

Based on EcoR1 Capital's 13F filing for Q1 2019, filed 15 May 2019.